USB | GenomeWeb

USB

StoneCalibre, a Los Angeles-based private investment firm, announced this week that it has acquired Affymetrix's Anatrace business unit. Financial details of the deal were not disclosed.

By Ben Butkus
ArcticZymes, a Norwegian life science research tools firm specializing in cold-adapted and heat-labile enzymes for use in molecular biology and diagnostics, this week opened its first US office in the outskirts of Philadelphia.

This story was originally posted on Nov. 3
By Justin Petrone

Acknowledging the challenges the firm faces and admitting it has been "slow to respond to technology changes" in the market, Frank Witney said the firm still has some opportunities to restore growth — if it positions its products correctly.

To make up for the "lumpiness" of the market for genome-wide association studies, Affy will focus on applications that are downstream from GWAS, particularly in validation and routine testing, according to President and CEO Kevin King, who also shed some light on Affy's recent decision to sell its Clinical Services Laboratory to Navigenics.

People in the News

Premium

Frank Witney, Paul Keim, Trilochan Sahoo, Jack Lord, Mari Baker, Patrick Terry, Lutz Kirchrath

Affy transferred ownership of the 10,000-square-foot Clinical Services Lab to Navigenics earlier this year though an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

People in the News

Premium

Frank Witney, Allen Bombard

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.